沛嘉醫療-B(09996.HK):完成TaurusWave®首次人體臨牀試驗首例患者治療
格隆匯10月22日丨沛嘉醫療-B(09996.HK)發佈公吿,2021年10月19日,公司於浙江大學醫學院附屬第二醫院完成TaurusWave®首次人體臨牀試驗的首例患者治療。
公司內部研發的在研產品TaurusWave®是世界領先的創新性非植入式經導管解決方案,用於治療鈣化性主動脈瓣狹窄。與傳統植入式方案不同,TaurusWave®應用衝擊波技術軟化瓣葉上的鈣化結構。公司將繼續臨牀試驗,為患者提供治療。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.